A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234) - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis – STOPGAP II (EA2234)

  • By

  • September 15, 2026

  • 1 min

Share

Clinical Report: STOPGAP II Tests Intraperitoneal Paclitaxel in Gastric Carcinomatosis

Overview

STOPGAP II (ECOG-ACRIN EA2234; NCT07001748) is a randomized phase II/III trial comparing intraperitoneal paclitaxel plus systemic treatment with systemic treatment alone in gastric carcinomatosis. The study is designed to assess whether adding paclitaxel delivered into the abdominal cavity can reduce cancer growth or spread and improve survival; no trial results are provided in the supplied material.

Background

The trial includes gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis. Its central question is whether regional intraperitoneal paclitaxel adds benefit to chemotherapy administered intravenously. The supplied contemporary guidance context describes systemic therapy as standard initial management for metastatic gastric or gastroesophageal junction adenocarcinoma, with treatment selection informed by biomarkers. Regional intraperitoneal approaches are described as options for selected patients in some guidance, while evidence from randomized studies of other intraperitoneal strategies has been mixed.

Data Highlights

ItemDetails
TrialSTOPGAP II (ECOG-ACRIN EA2234), randomized phase II/III
ClinicalTrials.gov identifierNCT07001748
Population/diseases listedGastric adenocarcinoma, gastroesophageal junction adenocarcinoma, and peritoneal carcinomatosis
ComparisonIntraperitoneal paclitaxel plus systemic treatment versus systemic treatment alone
Study questionsWhether intraperitoneal paclitaxel can lower the chance of cancer growth or spread and help patients live longer
ResultsNo efficacy or safety results are included in the supplied trial description

Key Findings

  • STOPGAP II is identified as a randomized phase II/III study, protocol 26-2004, with ClinicalTrials.gov identifier NCT07001748.
  • The experimental strategy adds paclitaxel administered directly into the abdominal cavity to systemic treatment given through a vein.
  • The comparator is systemic treatment alone.
  • The study description identifies reduction in cancer growth or spread and longer survival as questions the trial is intended to address, not as established outcomes.
  • The supplied context states that systemic therapy remains the standard initial management for metastatic gastric or gastroesophageal junction adenocarcinoma, with immunotherapy or targeted therapy selected according to biomarkers.
  • Evidence cited in the supplied context for other regional approaches is mixed: GASTRIPEC-I reported improved progression-free survival but no overall-survival benefit with CRS plus HIPEC versus CRS alone, while PERISCOPE II reported no overall-survival advantage for gastrectomy plus CRS and HIPEC versus continued systemic therapy.

Clinical Implications

The supplied material describes STOPGAP II as an investigational comparison and provides no results supporting a change in treatment. For clinical decisions, the context identifies systemic therapy as standard initial management and notes that regional approaches are considered in selected settings; trial eligibility inquiries are directed to the study contact.

Conclusion

STOPGAP II is evaluating whether intraperitoneal paclitaxel adds benefit to systemic treatment for gastric carcinomatosis. The supplied information describes the trial rationale and design but does not report outcomes.

Related Resources & Content

  1. ECOG-ACRIN/ASCO, Journal of Clinical Oncology, 2026 — A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234
  2. ClinicalTrials.gov, NCT07001748 — STOPGAP II (EA2234)
  3. Journal of Clinical Oncology, 2023 — Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial
  4. ASCO Publications — A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234.
  5. ASCO Publications — A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234.
  6. ASCO Publications — A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234.
  7. ASCO Publications — A phase II study of perioperative intraperitoneal paclitaxel plus S-1/paclitaxel for curatively resectable gastric cancer with serosal invasion: The GAPS study.
  8. STOPGAP II (EA2234), ClinicalTrials.gov NCT07001748
  9. STOPGAP II—ECOG-ACRIN EA2234, Journal of Clinical Oncology
  10. GASTRIPEC-I Phase III Trial, Journal of Clinical Oncology
  11. Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline
  12. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial | Journal of Clinical Oncology
  13. A randomized phase II/III trial of intraperitoneal paclitaxel plus systemic treatment vs systemic treatment alone in gastric carcinomatosis: STOPGAP II—ECOG-ACRIN EA2234. | Journal of Clinical Oncology

Original Source(s)

Related Content